104 related articles for article (PubMed ID: 9646644)
1. Skeletal scintigraphy in breast cancer management.
Bares R
Q J Nucl Med; 1998 Mar; 42(1):43-8. PubMed ID: 9646644
[TBL] [Abstract][Full Text] [Related]
2. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
3. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
4. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone.
Ghanem N; Uhl M; Brink I; Schäfer O; Kelly T; Moser E; Langer M
Eur J Radiol; 2005 Jul; 55(1):41-55. PubMed ID: 15950100
[TBL] [Abstract][Full Text] [Related]
6. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
7. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
Moog F; Kotzerke J; Reske SN
J Nucl Med; 1999 Sep; 40(9):1407-13. PubMed ID: 10492357
[TBL] [Abstract][Full Text] [Related]
8. [Radiologic detection of metastatic bone tumors].
Sugimoto E; Tamagawa M; Okawara K; Osawa T
Gan No Rinsho; 1988 Aug; 34(10):1491-7. PubMed ID: 3172506
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.
Kosmin M; Padhani AR; Gogbashian A; Woolf D; Ah-See ML; Ostler P; Sutherland S; Miles D; Noble J; Koh DM; Marshall A; Dunn J; Makris A
Radiology; 2020 Dec; 297(3):622-629. PubMed ID: 33078998
[TBL] [Abstract][Full Text] [Related]
10. [Skeletal scintigraphy in the care of breast cancer . Long-term follow-up over 8 years].
Anger K; Möller T; Zeimantz E
Strahlentherapie; 1983 Dec; 159(12):745-50. PubMed ID: 6665812
[TBL] [Abstract][Full Text] [Related]
11. Staging non-small cell lung cancer with whole-body PET.
Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
[TBL] [Abstract][Full Text] [Related]
12. A review of the efficacy of bone scanning in prostate and breast cancer.
O'Sullivan JM; Cook GJ
Q J Nucl Med; 2002 Jun; 46(2):152-9. PubMed ID: 12114879
[TBL] [Abstract][Full Text] [Related]
13. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
14. Skeletal metastases from breast cancer: imaging with nuclear medicine.
Cook GJ; Fogelman I
Semin Nucl Med; 1999 Jan; 29(1):69-79. PubMed ID: 9990685
[TBL] [Abstract][Full Text] [Related]
15. [What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?].
Turpin A; Mailliez A; Vennin P; Bonneterre J
Gynecol Obstet Fertil; 2014 May; 42(5):325-30. PubMed ID: 24411340
[TBL] [Abstract][Full Text] [Related]
16. [Fluoride-positron emission tomography/computed tomography for differential diagnosis in suspected bone metastasis].
Petersen H; Ogren M; Høilund-Carlsen PF
Ugeskr Laeger; 2010 May; 172(20):1538-9. PubMed ID: 20483103
[TBL] [Abstract][Full Text] [Related]
17. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease.
Horger M; Bares R
Semin Nucl Med; 2006 Oct; 36(4):286-94. PubMed ID: 16950146
[TBL] [Abstract][Full Text] [Related]
18. [Bone scintigraphy in metastatic bone disease].
Itoh K
Kaku Igaku; 2000 Jan; 37(1):1-5. PubMed ID: 10714061
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
